{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T13:56:26Z","timestamp":1777730186764,"version":"3.51.4"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00120-026-02810-x","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T13:48:05Z","timestamp":1774446485000},"page":"490-497","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Leitlinie \u201eHarnblasenkarzinom\u201c\u00a0\u2013 was gibt es Neues?","Perioperative therapy for muscle-invasive bladder cancer\u2014current treatment concepts"],"prefix":"10.1007","volume":"65","author":[{"given":"G\u00fcnter","family":"Niegisch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios","family":"Gakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carsten H.","family":"Ohlmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Kn\u00fcchel-Clarke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Beyersdorff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Rick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Golka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"Hegemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter J.","family":"Goebell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Maisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Gschwend","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"key":"2810_CR1","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF) (2025) S3-Leitlinie Fr\u00fcherkennung, Diagnose, Therapie und Nachsorge des Harnblasenkarzinoms, Langversion 3.0. https:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/harnblasenkarzinom. Accessed .9.2025"},{"key":"2810_CR2","unstructured":"(2022) The Paris System for Reporting Urinary Cytology, 2\u00a0edn. Springer, Cham"},{"issue":"3","key":"2810_CR3","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.euo.2020.02.007","volume":"3","author":"S Woo","year":"2020","unstructured":"Woo\u00a0S, Panebianco\u00a0V, Narumi\u00a0Y, Del Giudice\u00a0F, Muglia\u00a0VF, Takeuchi\u00a0M et\u00a0al (2020) Diagnostic Performance of Vesical Imaging Reporting and Data System for the Prediction of Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. Eur Urol Oncol 3(3):306\u2013315. https:\/\/doi.org\/10.1016\/j.euo.2020.02.007","journal-title":"Eur Urol Oncol"},{"key":"2810_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2022.110666","volume":"160","author":"AL Lai","year":"2023","unstructured":"Lai\u00a0AL, Law\u00a0YM (2023) VI-RADS in bladder cancer: Overview, pearls and pitfalls. Eur J Radiol 160:110666. https:\/\/doi.org\/10.1016\/j.ejrad.2022.110666","journal-title":"Eur J Radiol"},{"key":"2810_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15205040","author":"LA Tsikitas","year":"2023","unstructured":"Tsikitas\u00a0LA, Hopstone\u00a0MD, Raman\u00a0A, Duddalwar\u00a0V (2023) Imaging in Upper Tract Urothelial Carcinoma: A Review. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers15205040","journal-title":"Cancers (Basel)"},{"issue":"3","key":"2810_CR6","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.eururo.2012.05.048","volume":"62","author":"JJ Meeks","year":"2012","unstructured":"Meeks\u00a0JJ, Bellmunt\u00a0J, Bochner\u00a0BH, Clarke\u00a0NW, Daneshmand\u00a0S, Galsky\u00a0MD et\u00a0al (2012) A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. European urology 62(3):523\u2013533. https:\/\/doi.org\/10.1016\/j.eururo.2012.05.048","journal-title":"European urology"},{"issue":"12","key":"2810_CR7","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1007\/s00120-022-01870-z","volume":"61","author":"CH Ohlmann","year":"2022","unstructured":"Ohlmann\u00a0CH, Kerkmann\u00a0M, Holtmann\u00a0L, Gschwend\u00a0JE, Retz\u00a0M, de Wit\u00a0M (2022) Quality assurance for the treatment of muscle-invasive and metastasized bladder carcinoma in Germany : An initiative of the Working Groups Urological Oncology (AUO) and Internal Oncology (AIO) in the German Cancer Society (DKG). Urologie 61(12):1351\u20131364. https:\/\/doi.org\/10.1007\/s00120-022-01870-z","journal-title":"Urologie"},{"key":"2810_CR8","unstructured":"EAU Guidelines. Edn. presented at the EAU Annual Congress Madrid 2025ed ."},{"issue":"3","key":"2810_CR9","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","volume":"33","author":"T Powles","year":"2022","unstructured":"Powles\u00a0T, Bellmunt\u00a0J, Comperat\u00a0E, De Santis\u00a0M, Huddart\u00a0R, Loriot\u00a0Y et\u00a0al (2022) Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of oncology : official journal of the European Society for Medical Oncology \/ ESMO 33(3):244\u2013258. https:\/\/doi.org\/10.1016\/j.annonc.2021.11.012","journal-title":"Annals of oncology : official journal of the European Society for Medical Oncology \/ ESMO"},{"issue":"1","key":"2810_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/JU.0000000000003981","volume":"212","author":"J Holzbeierlein","year":"2024","unstructured":"Holzbeierlein\u00a0J, Bixler\u00a0BR, Buckley\u00a0DI, Chang\u00a0SS, Holmes\u00a0RS, James\u00a0AC et\u00a0al (2024) Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA\/ASCO\/SUO Guideline (2017; Amended 2020, 2024). The Journal of urology 212(1):3\u201310. https:\/\/doi.org\/10.1097\/JU.0000000000003981","journal-title":"The Journal of urology"},{"issue":"3","key":"2810_CR11","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S1470-2045(10)70275-8","volume":"12","author":"MD Galsky","year":"2011","unstructured":"Galsky\u00a0MD, Hahn\u00a0NM, Rosenberg\u00a0J, Sonpavde\u00a0G, Hutson\u00a0T, Oh\u00a0WK et\u00a0al (2011) A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. The Lancet Oncology 12(3):211\u2013214. https:\/\/doi.org\/10.1016\/S1470-2045(10)70275-8","journal-title":"The Lancet Oncology"},{"issue":"19","key":"2810_CR12","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","volume":"391","author":"T Powles","year":"2024","unstructured":"Powles\u00a0T, Catto\u00a0JWF, Galsky\u00a0MD, Al-Ahmadie\u00a0H, Meeks\u00a0JJ, Nishiyama\u00a0H et\u00a0al (2024) Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer. N\u00a0Engl J Med 391(19):1773\u20131786. https:\/\/doi.org\/10.1056\/NEJMoa2408154","journal-title":"N Engl J Med"},{"issue":"6","key":"2810_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2024.102176","volume":"22","author":"R O\u2019Dwyer","year":"2024","unstructured":"O\u2019Dwyer\u00a0R, Musat\u00a0MG, Gulas\u00a0I, Hubscher\u00a0E, Moradian\u00a0H, Guenther\u00a0S et\u00a0al (2024) Split-Dose Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Carcinoma: A Systematic Literature Review and Network Meta-Analysis. Clinical genitourinary cancer 22(6):102176. https:\/\/doi.org\/10.1016\/j.clgc.2024.102176","journal-title":"Clinical genitourinary cancer"},{"issue":"22","key":"2810_CR14","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","volume":"384","author":"DF Bajorin","year":"2021","unstructured":"Bajorin\u00a0DF, Witjes\u00a0JA, Gschwend\u00a0JE, Schenker\u00a0M, Valderrama\u00a0BP, Tomita\u00a0Y et\u00a0al (2021) Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. N\u00a0Engl J Med 384(22):2102\u20132114. https:\/\/doi.org\/10.1056\/NEJMoa2034442","journal-title":"N Engl J Med"},{"key":"2810_CR15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2511674","author":"C Vulsteke","year":"2026","unstructured":"Vulsteke\u00a0C, Adra\u00a0N, Danchaivijitr\u00a0P, Sabadash\u00a0M, Rodriguez-Vida\u00a0A, Zhang\u00a0Z et\u00a0al (2026) Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer. N\u00a0Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2511674","journal-title":"N Engl J Med"},{"issue":"10","key":"2810_CR16","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles\u00a0T, Valderrama\u00a0BP, Gupta\u00a0S, Bedke\u00a0J, Kikuchi\u00a0E, Hoffman-Censits\u00a0J et\u00a0al (2024) Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. N\u00a0Engl J Med 390(10):875\u2013888. https:\/\/doi.org\/10.1056\/NEJMoa2312117","journal-title":"N Engl J Med"},{"key":"2810_CR17","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF) (2023) Psychoonkologische Diagnostik, Beratung und Behandlung von erwachsenen Krebspatient*innen - Langversion 2.1. https:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/psychoonkologie\/. Accessed 16.1.2026"},{"key":"2810_CR18","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF) (2020) Palliativmedizin f\u00fcr Patienten mit einer nicht-heilbaren Krebserkrankung, Langversion 2.2, AWMF-Registernummer: 128\/001OL. https:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/palliativmedizin\/. Accessed 16.1.2026"},{"key":"2810_CR19","doi-asserted-by":"crossref","unstructured":"Zwakman M, Jabbarian LJ, van Delden J, van der Heide A, Korfage IJ, Pollock K et\u00a0al. Advance care planning: A\u00a0systematic review about experiences of patients with a\u00a0life-threatening or life-limiting illness. Palliat Med. 2018;32(8):1305\u201321. https:\/\/doi.org\/10.1177\/0269216318784474.","DOI":"10.1177\/0269216318784474"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-026-02810-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-026-02810-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-026-02810-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:57:43Z","timestamp":1777460263000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-026-02810-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2810"],"URL":"https:\/\/doi.org\/10.1007\/s00120-026-02810-x","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"value":"2731-7064","type":"print"},{"value":"2731-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"2 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"G.\u00a0Niegisch: Vortr\u00e4ge, Symposien: Roche Pharma, MEDAC, Pfizer, BMS, AstraZeneca, Merck, Johnson & Johnson, Astellas, medudy, medtoday, FOMF, solution Akademie; Advisory Boards: Roche Pharma, Sanofi, BMS, Merck Serono, Pfizer, MEDAC, Ipsen, Johnson & Johnson, Astellas, AstraZeneca, Novartis, MEDAC; Kongressunterst\u00fctzung: Roche Pharma, Pfizer, Merck, Johnson & Johnson, Ipsen; Manuskripte, Publikationen: Pfizer, BMS, Merck, Ferring; sonstiges: Koordinator S3-Leitlinie. G.\u00a0Gakis: Vortr\u00e4ge, Symposien: Astra Zeneca, Erbe Elektromedizin, Bristol-Myers Squibb, IPSEN Pharma, Leo Pharma, medac, Merck, MSD, Roche, CEA Alliance, Johnson & Johnson, Pfizer, Solution Akademie; Beratert\u00e4tigkeit: Astellas, Astra Zeneca, Johnson & Johnson, Bristol-Myers Squibb, IPSEN Pharma, Bayer, Pfizer, Roche, Leo Pharma, medac, Merck Serono, Merck, MSD, QED Therapeutics, Photocure; Kongressunterst\u00fctzung: Astellas, Astra Zeneca, IPSEN Pharma, Leo Pharma, MSD, Johnson & Johnson, Pfizer, Astellas, Bristol-Myers Squibb, Photocure, Merck, MSD, Merck. C.H.\u00a0Ohlmann: Vortr\u00e4ge, Symposien: MEDAC, Pfizer, Bayer, BMS, AstraZeneca, Merck, Johnson & Johnson, Astellas, medudy, FOMF, solution Akademie; Advisory Boards: Bayer, BMS, Merck Serono, Johnson & Johnson, Astellas, AstraZeneca, Novartis, MEDAC; Kongressunterst\u00fctzung: Bayer, Ipsen, Johnson & Johnson; Manuskripte, Publikationen: Astra Zeneca; Sonstiges: Mitglied S3-Leitlinie, DKG, DGU. K.\u00a0Golka: Vortr\u00e4ge: Akademien der \u00c4rztekammern. P.J.\u00a0Goebell: Advisory boards und Kongressunterst\u00fctzung: Accord, AstraZeneca, Astellas, Apogepha, Bayer, BMS, Cepheid, Eisai, EUSA, Hexal, Ipsen, Janssen-Cilag, Merck, MSD, Novartis, Pfizer, Recordati, Roche, Sandoz, Sanofi; Beratungen: Bayer, Ipsen, Novartis; Vortr\u00e4ge, Symposien Accord, AstraZeneca, Astellas, Apogepha, Bayer, BMS, Cepheid, Eisai, EUSA, Hexal, Ipsen, Janssen-Cilag, Merck, MSD, Novartis, Pfizer, Recordati, Roche, Sandoz, Sanofi, and Takeda. P.\u00a0Maisch: Kongressunterst\u00fctzung: Bayer. J.\u00a0Gschwend: Vortr\u00e4ge und Beratung: Astellas, Astra-Zeneca, Bayer, Ipsen, Janssen, Merck, MSD, Novartis, Pfizer, Roche. R.\u00a0Kn\u00fcchel-Clarke, D.\u00a0Beyersdorff, O.\u00a0Rick und M.\u00a0Hegemann geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}